14,800 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Premier Fund Managers Ltd

Premier Fund Managers Ltd acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 14,800 shares of the biotechnology company's stock, valued at approximately $5,307,000.

Several other large investors also recently modified their holdings of UTHR. Comerica Bank lifted its holdings in shares of United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company's stock worth $38,113,000 after purchasing an additional 9,244 shares in the last quarter. Tri Locum Partners LP acquired a new position in shares of United Therapeutics during the second quarter valued at about $15,959,000. QRG Capital Management Inc. grew its holdings in shares of United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company's stock valued at $4,880,000 after buying an additional 1,692 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of United Therapeutics by 567.2% during the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company's stock worth $41,533,000 after acquiring an additional 153,700 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock worth $692,748,000 after acquiring an additional 22,978 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a report on Friday, November 1st. HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Finally, LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $370.86.

United Therapeutics Price Performance

UTHR stock traded up $4.27 during mid-day trading on Wednesday, reaching $364.98. 40,875 shares of the company traded hands, compared to its average volume of 460,316. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The company has a market capitalization of $16.30 billion, a P/E ratio of 15.84, a P/E/G ratio of 1.06 and a beta of 0.56. The company has a fifty day moving average price of $363.50 and a 200-day moving average price of $330.09.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.38 earnings per share. As a group, analysts forecast that United Therapeutics Co. will post 25.1 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the transaction, the chief financial officer now owns 3,210 shares of the company's stock, valued at approximately $1,108,766.10. This trade represents a 70.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christopher Causey sold 510 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares in the company, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,796 shares of company stock valued at $40,936,370. Corporate insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.